Pfizer (Germany)
Impact in
-
- Diabetes Treatment and Management
- Nephrology top 10%
- Dialysis and Renal Disease Management
Papers in
- Microbiology 30
- Bacterial Infections and Vaccines 20
- Epidemiology 142
- Pneumonia and Respiratory Infections 79
- Respiratory viral infections research 39
- Top scholars
- Rainer FreynhagenRalf BaronUlrich GockelThomas R. TölleJürgen VollmerWinfried MärzG. RufVera Krane
- Journals
- Mycoses (33 papers)Vaccine (28 papers)Value in Health (22 papers)Journal of Clinical Oncology (22 papers)Annals of the Rheumatic Diseases (15 papers)
- Partner nations
- GermanyUnited StatesUnited Kingdom
In The Last Decade
Pfizer (Germany)
573 papers receiving 16.1k citations
Peers
Comparison fields: 5 of 200
- Endocrinology, Diabetes and Metabolism 2.4k
- Nephrology 903
- Epidemiology 3.4k
- Microbiology 581
- Pharmacology 1.3k
Countries citing scholars working at Pfizer (Germany)
This map shows the geographic impact of research produced by authors working at Pfizer (Germany). It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by papers produced at Pfizer (Germany) with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pfizer (Germany) more than expected).
Fields of papers published by authors at Pfizer (Germany)
This network shows the impact of papers affiliated with Pfizer (Germany) at the time of their publication. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers affiliated with Pfizer (Germany) at the time of their publication.
About Pfizer (Germany)
In recent decades, authors affiliated with Pfizer (Germany) have published 674 papers, which have received a total of 19.2k indexed citations . Scholars at this organization have produced 30 papers in Microbiology, 142 papers in Epidemiology, 6 papers in Health Informatics, 27 papers in Parasitology and 71 papers in Infectious Diseases on the topics of Pneumonia and Respiratory Infections (79 papers), Respiratory viral infections research (39 papers), Antifungal resistance and susceptibility (35 papers), Health Systems, Economic Evaluations, Quality of Life (29 papers), Vector-borne infectious diseases (23 papers), Renal cell carcinoma treatment (20 papers), Bacterial Infections and Vaccines (20 papers) and Rheumatoid Arthritis Research and Therapies (19 papers). Their work is cited by papers focused on Endocrinology, Diabetes and Metabolism (2.4k citations), Nephrology (903 citations), Epidemiology (3.4k citations), Microbiology (581 citations) and Pharmacology (1.3k citations). Authors at Pfizer (Germany) collaborate with scholars in Germany, United States and United Kingdom and have published in prestigious journals including Mycoses, Vaccine, Value in Health, Journal of Clinical Oncology and Annals of the Rheumatic Diseases. Some of Pfizer (Germany)'s most productive authors include Rainer Freynhagen, Ralf Baron, Ulrich Gockel, Thomas R. Tölle, Jürgen Vollmer, Winfried März, G. Ruf, Vera Krane, Manfred Olschewski and Christoph Wanner.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.